Imagine a
world without allergies
Desentum’s mission is to expand the use of allergen immunotherapy (AIT) world-wide by introducing novel, effective, safe and patient-friendly AIT products that are well-documented and approved by the regulatory authorities. Our lead development programs include treatments for birch pollen, peanut, and cat allergies.
Desentum’s products are investigational and not approved for marketing in any region.
Technology
Our immunotherapeutic products consist of recombinant allergens specifically modified to suppress the histamine release during the desensitization process. They can significantly reduce the risk of serious adverse effects and the time required for immunotherapy.
Desentum
Desentum is a clinical-stage biopharmaceutical company developing novel types of allergen immunotherapy products that actually change the way the immune system reacts to allergens. We have a unique technology that can lead to major improvements in the future treatment of allergies.
News
Desentum raises €28 million to develop safer, more effective allergen immunotherapy
The round, arranged by Finnish investment firm Springvest, is one of the largest ever raised by a privately held Finnish drug development company.
New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX
A scientific paper reporting the Phase 1 clinical trial results of DM-101PX has been published in the renowned journal Clinical & Experimental Allergy.
Desentum to present at the 2026 EAACI annual congress in Istanbul this week
Two abstracts related to Desentum’s product development projects have been accepted for presentation at the annual...